Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has received an average rating of “Moderate Buy” from the six analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $39.00.

A number of analysts have recently issued reports on ARTV shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Friday, April 24th. HC Wainwright increased their target price on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Wall Street Zen downgraded Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Finally, Wedbush raised their target price on Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research note on Monday, May 11th.

Insider Buying and Selling

In related news, CEO Fred Aslan sold 27,116 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $9.01, for a total transaction of $244,315.16. Following the completion of the transaction, the chief executive officer owned 1,535,082 shares of the company’s stock, valued at $13,831,088.82. This trade represents a 1.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Corp. Gc bought 1,085,069 shares of the company’s stock in a transaction on Monday, May 11th. The stock was bought at an average cost of $11.52 per share, for a total transaction of $12,499,994.88. Following the completion of the acquisition, the insider directly owned 4,391,969 shares of the company’s stock, valued at approximately $50,595,482.88. This represents a 32.81% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 9,534,631 shares of company stock worth $104,042,163 and sold 53,040 shares worth $477,890. 21.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of hedge funds have recently bought and sold shares of ARTV. Bank of America Corp DE boosted its stake in Artiva Biotherapeutics by 225.8% during the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock valued at $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $41,000. Dimensional Fund Advisors LP bought a new stake in shares of Artiva Biotherapeutics in the first quarter worth approximately $131,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Artiva Biotherapeutics during the fourth quarter valued at approximately $91,000. Finally, Sanctuary Advisors LLC bought a new stake in Artiva Biotherapeutics in the 1st quarter worth approximately $139,000.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV remained flat at $9.61 during midday trading on Friday. The stock had a trading volume of 435,839 shares, compared to its average volume of 703,898. The firm has a 50-day moving average price of $9.12 and a two-hundred day moving average price of $6.78. The stock has a market capitalization of $237.56 million, a P/E ratio of -2.71 and a beta of 2.18. Artiva Biotherapeutics has a 52 week low of $1.55 and a 52 week high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its earnings results on Friday, May 8th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.07). On average, equities research analysts forecast that Artiva Biotherapeutics will post -2.45 earnings per share for the current year.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.